Drug Profile
Research programme: encapsulated enzyme therapeutics - PHAXIAM Therapeutic/Sanofi
Alternative Names: ERY-ERTLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator ERYtech Pharma; Genzyme Corporation
- Developer PHAXIAM Therapeutics; Sanofi
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 13 Sep 2022 Encapsulated enzyme therapeutics is still in preclinical phase for Metabolic disorders in France
- 28 Sep 2018 No recent reports of development identified for preclinical development in Metabolic-disorders in France (Parenteral)